Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stone, John H., Merkel, Peter A., Spiera, Robert, Seo, Philip, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G.M., St. Clair, E. William, Turkiewicz, Anthony, Tchao, Nadia K., Webber, Lisa, Ding, Linna, Sejismundo, Lourdes P., Mieras, Kathleen, Weitzenkamp, David, Ikle, David, Seyfert-Margolis, Vicki, Mueller, Mark, Brunetta, Paul, Allen, Nancy B., Fervenza, Fernando C., Geetha, Duvuru, Keogh, Karina A., Kissin, Eugene Y., Monach, Paul A., Peikert, Tobias, Stegeman, Coen, Ytterberg, Steven R., Specks, Ulrich
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3137658/
https://ncbi.nlm.nih.gov/pubmed/20647199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0909905
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados